Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-053351

President & CEO sold 47,853 shares at $33.52 ($1,604,033)

  • President & CEO acquired 47,853 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

KAKKIS EMIL D · President & CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-10-19 Exercise or conversion : show line 1 in the form +47,853 $6.86 $328,272 647,029 D
2023-10-19 Sale : show line 2 in the form −47,853 $33.52 $1,604,033 599,743 D
Open-market sales · 47,853 sh · avg $33.52 · $1,604,033

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-10-19 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −47,853 0 D
Loading xslF345X05/doc4.xml…